ISARIC - Coronavirus Clinical Characterisation Consortium (ISARIC-4C)

Grant number: MC_PC_19025

Grant search

Key facts

  • Disease

  • Start & end year

  • Known Financial Commitments (USD)

  • Funder

    UK Research and Innovation (UKRI)
  • Principle Investigator

  • Research Location

    United Kingdom, Europe
  • Lead Research Institution

    University of Edinburgh
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory


  • Special Interest Tags


  • Study Subject


  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment


  • Age Group


  • Vulnerable Population


  • Occupations of Interest



This award is being made in support of urgent research costs to enable sampling amongst UK COVID-19 cases. This is essential in developing diagnostics, therapeutics (monoclonal antibodies) and understanding the pathogen and the natural history of the disease, as well as developing rapid prognostic tools. This funding support will ensure samples are distributed safely to researchers. Research could change the course of the rapidly spreading outbreak.

Publicationslinked via Europe PMC

Last Updated:41 minutes ago

View all publications at Europe PMC

Evaluation of pragmatic oxygenation measurement as a proxy for Covid-19 severity.

Patient emergency health-care use before hospital admission for COVID-19 and long-term outcomes in Scotland: a national cohort study.

CAGE sequencing reveals CFTR-dependent dysregulation of type I IFN signaling in activated cystic fibrosis macrophages.

Neurological manifestations of COVID-19 in adults and children.

Adeno-associated virus 2 infection in children with non-A-E hepatitis.

Variation in ERAP2 has opposing effects on severe respiratory infection and autoimmune disease.

Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study.

Comorbidities, multimorbidity and COVID-19.

Estimating distribution of length of stay in a multi-state model conditional on the pathway, with an application to patients hospitalised with Covid-19.